Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Randviken Fastigheter AB (publ) in connection with its change of company object and re-listing on Nordic SME
Mandate

Vinge has advised Randviken Fastigheter AB (publ) in connection with its change of company object and re-listing on Nordic SME

September 10, 2021 Banking and Finance Capital Markets and Public M&A Real Estate and Construction

Vinge advises Randviken Fastigheter AB (publ) (”Randviken”) in connection with its change of company object and re-listing on Nordic SME (Nordic Growth Market). The Company Description was made public on 31 August 2021. The change of the company object was due to an indirect acquisition of 35 properties amounting to a total value of SEK 2,778 million.

Randviken is a real estate company with the aim to acquire, manage and refine properties in different segments and geographical locations. In addition to Randviken’s primary focus on stable and long-term cash flows from rented premises, the company’s ambition is to actively engage with intelligent technology to achieve more sustainable and energy efficient properties.

Randviken is listed on Nordic SME (Nordic Growth Market).

Vinges team included David Andersson, Julia Hirschberg and Olivia Belding (Capital Markets and Public M&A), Niclas Winnberg, Kristoffer Larson, Frida Ställborn and Ulf Pyk (Real Estate), as well as Fabian Ekeblad, Paulina Malmberg and Elin Samara (Banking and Finance).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025